Despite compelling data from trials like PATINA, some patients with ER+/HER2+ breast cancer refuse maintenance endocrine therapy due to side effects. This highlights a real-world gap between clinical trial evidence and patient adherence, forcing oncologists to navigate patient preferences against optimal treatment protocols.

Trials like TaylorX and MINDACT use genomic scores to identify patients with early-stage, HR+/HER2- breast cancer who won't benefit from adjuvant chemotherapy. This avoids significant toxicity for two-thirds to over 80% of patients who would have received it under older guidelines, without compromising their outcomes.

For premenopausal patients with extensive nodal disease (e.g., N2), the clinical indication for chemotherapy is so strong that even a low-risk genomic score would not be enough to withhold treatment. This highlights the primacy of clinical staging over genomic data in certain high-risk scenarios.

The rapid evolution of clinical evidence is reflected in ASCO guidelines. In just one year (2022 to 2023), recommendations for ESR1 testing in HR+ metastatic breast cancer changed from having insufficient data to recommending routine testing upon progression, highlighting the pace of change in oncology.

The SET assay, measuring estrogen receptor activity, re-analyzed the NSABP B42 trial and found a 'very high SET' subgroup. This group experienced a massive 17% absolute improvement in 10-year breast cancer-free interval with extended letrozole, unmasking a profound benefit that was diluted in the overall trial results.

Clinicians increasingly perform Next-Generation Sequencing (NGS) on initial diagnostic tissue, even if results don't alter first-line treatment. This proactive approach identifies stable mutations like PIK3CA early, enabling long-term planning, such as optimizing a patient's metabolic health in anticipation of future targeted therapies.

An AI model integrating digitized slide images, clinical data, and a 42-gene panel provides superior prognostic accuracy for early, late, and overall breast cancer recurrence compared to using the 21-gene score alone. This multimodal approach represents the future of risk assessment.

The SERINA-6 trial supports a paradigm shift: proactively screening for ESR1 mutations via blood test and switching to camisestrant upon detection, even without radiological progression. This early switch based on molecular signals nearly doubled median progression-free survival from 9 to 16 months.

A Mayo Clinic study found that FES-PET scan results led to a change in medical therapy, surgery, or radiation for 37% of patients with invasive lobular carcinoma. This demonstrates the technology's immediate, significant impact on clinical decision-making, going beyond mere diagnostic clarification to actively reshape patient care pathways.